Esketamine hydrochloride is a vital drug to be used for treating mental illness and is likely to significantly impact the LATAM market
The first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
India’s first trial for a novel autologous BCMA directed CAR-T cell therapy in patients with relapsed / refractory multiple myeloma
India called for stronger investments in health and social equity at G20 Joint Finance-Health Task Force Meeting
Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings
The approved product has an estimated market size of US$ 268 million for the twelve months ending June 2024, according to IQVIA
Rusan’s API facility in Ankleshwar is GMP approved by other stringent international agencies as well
The acquisition is immediately accretive and creates a compelling, single-stop, multi-continent partner for biopharma companies
Subscribe To Our Newsletter & Stay Updated
